Bio-Rad Laboratories (NYSE:BIO.B) Announces Earnings Results

Bio-Rad Laboratories (NYSE:BIO.B) announced its quarterly earnings results on Wednesday. The company reported $2.65 earnings per share (EPS) for the quarter, Zacks reports. The company had revenue of $656.40 million during the quarter. Bio-Rad Laboratories had a return on equity of 3.54% and a net margin of 8.59%.

Bio-Rad Laboratories Price Performance

Shares of NYSE BIO.B remained flat at $379.50 during midday trading on Thursday. The stock had a trading volume of 27 shares, compared to its average volume of 38. The firm has a fifty day simple moving average of $366.93 and a two-hundred day simple moving average of $312.31. The company has a market cap of $10.15 billion, a P/E ratio of 46.00 and a beta of 1.00. Bio-Rad Laboratories has a 1-year low of $244.54 and a 1-year high of $379.50. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.33 and a current ratio of 3.14.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (NYSE: BIO.B) develops, manufactures and markets products and systems used in life science research and clinical diagnostics. The company serves academic, pharmaceutical, biotechnology, industrial and healthcare customers with laboratory instruments, reagents, consumables, software and related services.

Its life science portfolio includes technologies for genomics, digital PCR, protein analysis, chromatography, electrophoresis, cell biology and imaging. Bio-Rad’s clinical diagnostics business provides systems and reagents used in areas such as diabetes monitoring, blood typing, quality control, infectious disease testing and autoimmune diagnostics.

Founded in 1952 by David and Alice Schwartz, Bio-Rad is headquartered in Hercules, California, and serves customers through operations and distribution networks in North America, Europe, Asia-Pacific and other international markets.